Concentrations of ceftriaxone in cerebrospinal fluid of children with meningitis receiving dexamethasone therapy.

AUTOR(ES)

Gaillard, J L

RESUMO

The penetration of ceftriaxone into cerebrospinal fluid (CSF) was studied with 11 children (mean age: 2 years, 4 months; range: 4 months to 8 years) with meningitis, receiving dexamethasone (0.15 mg/kg of body weight intravenously four times daily) as adjunctive therapy. Ceftriaxone was given intravenously at doses of 50 mg/kg twice daily to patients < 18 months old and 100 mg/kg once daily to patients > or = 18 months old. CSF was collected after 1 day of treatment at the expected peak concentration of ceftriaxone in CSF. Concentrations of ceftriaxone in CSF ranged from 0.7 to 9.2 mg/liter, with a mean value of 4.0 (standard deviation [SD], 2.9) mg/liter. Values were significantly higher for patients with CSF glucose levels of < 1 mmol/liter on admission to the hospital than for patients with CSF glucose levels of > or = 1 mmol/liter (mean values of 7.1 [SD, 2.2] mg/liter versus 2.2 [SD, 1.1] mg/liter; P < 0.001). After 1 day of treatment, ceftriaxone concentrations in the CSF of children receiving dexamethasone are similar to the mean values reported for children not treated with dexamethasone.

Documentos Relacionados

• Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis.
• Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis
• Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis
• Concentrations of Cefpirome in Cerebrospinal Fluid of Children with Bacterial Meningitis after a Single Intravenous Dose
• Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally.